Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arry-334543
1. 845272-21-1
2. Arry-334543
3. Arry334543
4. Arry 334543
5. Arry-543
6. Aslan-001
7. Varlitinib (arry334543)
8. Aslan001
9. 846y8197w1
10. Ar-00334543
11. (r)-n4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-n6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
12. 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
13. N(sup 4)-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-n(sup 6)-((4r)-4-methyl-4,5-dihydrooxazol-2- Yl)quinazoline-4,6-diamine
14. (r)-n4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-n6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
15. Varlitinib [usan]
16. Varlitinib [usan:inn]
17. Unii-846y8197w1
18. Varlitinib Free Base
19. Varlitinib [inn]
20. Varlitinib (usan/inn)
21. Varlitinib [who-dd]
22. Mls006011274
23. Gtpl7645
24. Schembl1384578
25. Chembl2103842
26. Dtxsid501025597
27. Ex-a1005
28. Vib27221
29. Bdbm50205268
30. Nsc764823
31. Nsc800962
32. S2755
33. Zinc13980035
34. Akos027250815
35. Ccg-269421
36. Cs-5222
37. Db05944
38. Nsc-764823
39. Nsc-800962
40. Ncgc00346724-01
41. Ncgc00346724-02
42. Ac-35277
43. Hy-10530
44. Smr004703024
45. Sw219901-1
46. D09689
47. A900002
48. Q27089126
49. (r)-4-[[3-chloro-4-[(thiazol-2-yl)methoxy]phenyl]amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline;varlitinib
50. 4,6-quinazolinediamine, N(sup 4)-(3-chloro-4-(2-thiazolylmethoxy)phenyl)-n(sup 6)-((4r)-4,5- Dihydro-4-methyl-2-oxazolyl)-
51. 4,6-quinazolinediamine, N(sup 4)-(3-chloro-4-(2-thiazolylmethoxy)phenyl)-n(sup 6)-((4r)-4,5-dihydro-4-methyl-2-oxazolyl)-
52. 4,6-quinazolinediamine, N4-(3-chloro-4-(2-thiazolylmethoxy)phenyl)-n6-((4r)-4,5-dihydro-4-methyl-2-oxazolyl)-
53. N4-(3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl)-n6-((4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl)quinazoline-4,6-diamine
| Molecular Weight | 466.9 g/mol |
|---|---|
| Molecular Formula | C22H19ClN6O2S |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 466.0978727 g/mol |
| Monoisotopic Mass | 466.0978727 g/mol |
| Topological Polar Surface Area | 122 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 660 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified).
Varlitinib is an orally active, reversible, enzymatic and cellular inhibitor, with nanomolar potency, of the key growth factor receptor tyrosine kinases ErbB-2 and EGFR. The compound possesses improved physiochemical properties relative to compounds directed at these targets currently in clinical development, and provides superior exposure and equivalent or greater efficacy in animal models of human cancer. Currently, there is no single drug on the market that selectively inhibits both ErbB-2 and EGFR. Varlitinib, which concurrently inhibits the molecular targets of the drugs Herceptin(R) (ErbB-2) and Erbitux(R) (EGFR), may provide enhanced efficacy in the treatment of cancer patients.
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
18
PharmaCompass offers a list of Varlitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Varlitinib manufacturer or Varlitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Varlitinib manufacturer or Varlitinib supplier.
PharmaCompass also assists you with knowing the Varlitinib API Price utilized in the formulation of products. Varlitinib API Price is not always fixed or binding as the Varlitinib Price is obtained through a variety of data sources. The Varlitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Varlitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Varlitinib, including repackagers and relabelers. The FDA regulates Varlitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Varlitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Varlitinib supplier is an individual or a company that provides Varlitinib active pharmaceutical ingredient (API) or Varlitinib finished formulations upon request. The Varlitinib suppliers may include Varlitinib API manufacturers, exporters, distributors and traders.
Varlitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Varlitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Varlitinib GMP manufacturer or Varlitinib GMP API supplier for your needs.
A Varlitinib CoA (Certificate of Analysis) is a formal document that attests to Varlitinib's compliance with Varlitinib specifications and serves as a tool for batch-level quality control.
Varlitinib CoA mostly includes findings from lab analyses of a specific batch. For each Varlitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Varlitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Varlitinib EP), Varlitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Varlitinib USP).
